MetaCap

Allogene Therapeutics (ALLO) vs Inhibikase Therapeutics (IKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inhibikase Therapeutics (IKT) has outperformed Allogene Therapeutics (ALLO) over the past year, losing 11.4% versus a loss of 49.0%. Over five years, IKT leads with a -89.3% price change compared with -96.5% for ALLO. Allogene Therapeutics is the larger company by market cap ($217.5 million vs $185.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLO-48.97%IKT-11.41%
+159%+50%-59%
Nov 21, 20251 yearNov 20, 2026
ALLO-96.66%IKT-88.42%
+14%-44%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLO versus IKT key metrics
MetricALLOIKT
Share price$0.6277$1.32
Market cap$217.48M$185.16M
1-day change-5.88%+1.54%
YTD return-54.18%-35.61%
1-year return-48.97%-11.41%
5-year return-96.51%-89.32%
EPS (TTM)$-0.61$-0.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-190.89M$-48.26M
52-week high$4.46$2.61
52-week low$0.6192$1.28
Distance from 52-week high-85.93%-49.43%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1333.81%+320.45%
Average volume7.69M584.27K
Shares outstanding346.47M140.27M
Employees15035
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IKT has outperformed ALLO by 37.6 percentage points over the past year.

About Allogene Therapeutics

ALLO stock →

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees

About Inhibikase Therapeutics

IKT stock →

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

ALLO vs IKT FAQ

Which is bigger, Allogene Therapeutics or Inhibikase Therapeutics?

Allogene Therapeutics (ALLO) is larger, with a market capitalization of $217.48M compared with $185.16M for Inhibikase Therapeutics (IKT).

Which stock has performed better over the past year, ALLO or IKT?

IKT returned -11.41% over the past 12 months, compared with -48.97% for ALLO (price return, excluding dividends). Past performance does not predict future results.

Are Allogene Therapeutics and Inhibikase Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons